CTLA4 and hepatocellular carcinoma: In 2020, the FDA granted orphan drug designation to the PD-L1 antibody durvalumab (Imfinzi) and the CTLA-4 inhibitor tremelimumab (Imjudo) for first-line treatment of HCC.